Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Historic VEGF inhibitors in lung cancer improved progression-free survival without yielding overall survival gains. The phase 3 HARMONY-6 trial broke this pattern by showing a statistically and clinically significant median overall survival improvement of 27 versus 23 months (hazard ratio 0.66) when combining ivonescimab with chemotherapy.

Related Insights

Frontline VEGF inhibition was historically avoided in squamous non-small cell lung cancer due to severe bleeding risks. In the HARMONY-6 study, excluding patients with large cavitary lesions or significant hemoptysis kept severe grade 3 or higher hemorrhage and arterial thromboembolism uncommon.

The bispecific antibody Ivanesimab binds to the VEGF dimer, creating a "daisy chain" of antibody-VEGF complexes. This multimerization concentrates the drug in the tumor microenvironment, where VEGF is high, and enhances its ability to bind and block PD-1 more effectively than single-molecule approaches.

The HARMONY-2 study showed Ivanesimab delivered a median progression-free survival of 11.3 months compared to 5.8 months for Pembrolizumab in PD-L1 positive NSCLC. Analysis confirmed Pembrolizumab performed as expected, suggesting the dual VEGF/PD-1 blockade provides a genuinely superior clinical benefit over PD-1 inhibition alone.

Patients with EGFR-mutated lung cancer progressing on frontline TKIs frequently exhibit CNS metastases and historically respond poorly to checkpoint inhibitors. In the HARMONY trial, adding ivonescimab to chemotherapy preserved progression-free survival benefits and actually produced greater additive benefit in patients presenting with brain metastases.

Due to a 10-11 month overall survival benefit shown in the FLORA two regimen, leading oncologists now consider osimertinib plus chemotherapy the standard first-line treatment for metastatic EGFR-mutant NSCLC. Monotherapy is reserved only for patients who cannot tolerate or refuse chemotherapy.

In the HARMONY A study, Ivanesimab plus chemotherapy significantly improved progression-free survival in EGFR-mutant non-small cell lung cancer patients. This is notable because prior trials showed that adding standard PD-1 inhibitors to chemotherapy was ineffective for this specific patient population.

Simultaneous targeting of VEGF and checkpoint inhibition raised concerns regarding compounded toxicities, but clinicians view the side-effect profile as familiar. Polling and trial results suggest ivonescimab's VEGF-related toxicities remain mostly low grade and are comparable to or more manageable than historical monoclonal antibodies like bevacizumab.

Bevacizumab is conventionally avoided in squamous non-small cell lung cancer due to fatal hemoptysis risks. Ivonescimab, a bispecific antibody targeting PD-1 and VEGF, relies on cooperative binding: VEGF enhances its PD-1 binding and PD-1 enhances VEGF binding. This concentrates VEGF and checkpoint blockade directly at the tumor microenvironment while sparing non-target tissues, producing statistically significant progression-free and overall survival gains in squamous disease without typical anti-VEGF vascular fatalities.

Unlike bevacizumab's long 20-day half-life and associated bleeding risks that excluded squamous cell carcinoma patients, new bispecifics have a ~6-day half-life. This results in a similar but less severe toxicity profile, broadening their clinical application to a wider patient population.

The next wave in NSCLC immunotherapy involves bispecific antibodies, which are single molecules that simultaneously block both the PD-1/PD-L1 and VEGF pathways. Agents like Ivanesimab are showing superior progression-free survival compared to standard checkpoint inhibitors, establishing this dual-target approach as a leading area of development.